HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Administration of Aspirin as a Prophylaxis Agent Against Venous Thromboembolism Results in Lower Incidence of Periprosthetic Joint Infection.

Abstract
The efficacy and safety of aspirin (ASA) for prevention of venous thromboembolism (VTE) following total joint arthroplasty (TJA) have been demonstrated. Our hypothesis was that postoperative ASA compared to warfarin lowers the incidence of periprosthetic joint infection (PJI). Between January 2006 and December 2012, 1456 patients received ASA and 1700 patients received warfarin following primary TJA as standard VTE prophylaxis. Logistic regression was utilized to identify independent risk factors of PJI. Incidence of PJI was significantly lower at 0.4% in patients receiving ASA vs. 1.5% in patients receiving warfarin (P<0.001). Warfarin and elevated BMI were independent risk factors for PJI following TJA (P<0.05). Our research suggests that the use of ASA compared to warfarin for VTE prophylaxis reduces the risk of PJI following TJA.
AuthorsRonald Huang, Patrick S Buckley, Benjamin Scott, Javad Parvizi, James J Purtill
JournalThe Journal of arthroplasty (J Arthroplasty) Vol. 30 Issue 9 Suppl Pg. 39-41 (Sep 2015) ISSN: 1532-8406 [Electronic] United States
PMID26182982 (Publication Type: Journal Article)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Anticoagulants
  • Warfarin
  • Aspirin
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
  • Anticoagulants (therapeutic use)
  • Aspirin (therapeutic use)
  • Female
  • Humans
  • Incidence
  • Joint Prosthesis (adverse effects)
  • Logistic Models
  • Male
  • Middle Aged
  • Prosthesis-Related Infections (epidemiology, prevention & control)
  • Retrospective Studies
  • Risk Factors
  • Venous Thromboembolism (etiology, prevention & control)
  • Warfarin (therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: